Detalles de la búsqueda
1.
Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
Clin Gastroenterol Hepatol
; 21(1): 153-163.e12, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842121
2.
Burden of disease among patients with prevalent Crohn's disease: results from a large German sickness fund.
Int J Colorectal Dis
; 38(1): 74, 2023 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36939923
3.
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
Clin Gastroenterol Hepatol
; 20(12): 2858-2867.e5, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35276329
4.
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
Scand J Gastroenterol
; 50(1): 113-20, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25523561
5.
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Aliment Pharmacol Ther
; 59(2): 175-185, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38036946
6.
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
United European Gastroenterol J
; 11(5): 410-422, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37139642
7.
Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims data.
Therap Adv Gastroenterol
; 15: 17562848221130554, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36353736
8.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Lancet Gastroenterol Hepatol
; 7(4): 294-306, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35120656
9.
Genetic predisposition to thrombophilia in inflammatory bowel disease.
J Clin Gastroenterol
; 45(3): e25-9, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20717043
10.
Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review.
Eur J Gastroenterol Hepatol
; 33(8): 1082-1090, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34213505
11.
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.
Eur J Intern Med
; 37: 83-89, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27773555
12.
Splenic littoral cell hemangioendothelioma in a patient with Crohn's disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immunosuppression.
Am J Gastroenterol
; 106(10): 1863-5, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21979217
13.
Integrins and adhesion molecules as targets to treat inflammatory bowel disease.
Curr Opin Pharmacol
; 25: 67-71, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26687159
14.
Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey.
Clin Med Insights Gastroenterol
; 7: 25-31, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24966712
15.
Randomized controlled clinical trials in mild-moderate ulcerative colitis.
Rev Recent Clin Trials
; 7(4): 256-69, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23092229
Resultados
1 -
15
de 15
1
Próxima >
>>